Author

Isharat Yusuf

Observed names: I. Yusuf, Yusuf, Isharat

Institution: Gossamer Bio (United States)

Observed institution: Gossamer Bio (United States)

OpenAlex ID: A5039478407

Bruton’s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination

2023 · Kirsten Scarlett Evonuk, Sen Wang, et al. · Acta Neuropathologica Communications · 12

An orally bioavailable ENPP1-selective inhibitor demonstrates superior immune preservation effects over STING agonists and confers antitumor efficacy in combination with other therapies in syngeneic tumor models

2022 · X. Hu, E. Garcia, et al. · European Journal of Cancer · 4

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

2022 · Carole Soussain, Samar Issa, et al. · Blood · 1

Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects

2022 · Brian J Kirby, Richard Aranda, et al. · Blood

GB5121, a Brain-Penetrant, Irreversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in a Novel Mouse Model of Intracranial Lymphoma

2022 · Isharat Yusuf, Marcos W Steinberg, et al. · Blood

Dddr-37. Gb5121 Is a Novel, Irreversible, Covalent Btk Inhibitor With High Selectivity and Cns-penetrance for Treatment of Cns Malignancies

2022 · Isharat Yusuf, David Guimond, et al. · Neuro-Oncology

Bsci-11 Gb5121 Is a Novel, Irreversible, Covalent Btk Inhibitor With High Selectivity and Cns-penetrance for Treatment of Cns Malignancies

2022 · Isharat Yusuf, David Guimond, et al. · Neuro-Oncology Advances

Clrm-15 Trial in Progress: a Phase 1b/2 Study of Gb5121, a Novel, Highly Selective, Potent, and Cns-penetrant Inhibitor of Bruton’s Tyrosine Kinase (btki) for Relapsed/refractory Primary/secondary Cns Lymphoma (r/r Pcnsl/scnsl) and Primary Vitreoretinal Lymphoma (pvrl)

2022 · Carole Soussain, Christian Grommes, et al. · Neuro-Oncology Advances

Abstract 3330: GB5121 is a novel highly potent and selective CNS-penetrant BTK inhibitor for CNS malignancies

2022 · Isharat Yusuf, Sunil Sahdeo, et al. · Cancer Research

P1247: Gb5121 Is a Novel, Irreversible, Covalent Btk Inhibitor With High Selectivity and Cns-penetrance for Treatment of Cns Malignancies

2022 · I. Yusuf, D. Guimond, et al. · HemaSphere

Works count: 13

Citation count: 17

H-index: 2

I10-index: 1